3SBio announces share placing to fund R&D and operations

On December 2, 2025, 3SBio Inc. entered a placing agreement with Morgan Stanley Asia Limited to issue 105,169,500 new shares at HK$29.62 per share. This represents a 6.50% discount to the closing price of HK$31.68 on the immediately preceding trading day and a 5.29% discount to the average closing price over the last five trading days. The placing shares will represent approximately 4.32% of the total shares in issue and 4.14% of the enlarged share capital.

The gross proceeds from the placing are estimated at HK$3.12bn, with net proceeds of approximately HK$3.09bn. 3SBio plans to allocate 80% (HK$2.47bn) of the net proceeds to R&D-related expenditures, including advancing clinical research in China and the United States for innovative drug candidates and supporting indication expansions for commercialized drugs.

The remaining 20% (HK$617.37m) will be used for working capital and other general corporate purposes to support the group's ongoing operations and strategic initiatives. The placing is conditional upon the Stock Exchange granting listing and permission to deal in the new shares.